ForSight Robotics vs Truvian Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching 2026;
About
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Truvian Health received FDA 510(k) clearance for its TruVerus benchtop blood analyzer in Dec 2025; raised $74M in July 2024 and is partnering with Shoppers Drug Mart for commercial rollout.
About
Truvian Health is a San Diego-based medical diagnostics company developing an automated benchtop blood testing platform that delivers lab-accurate results from a few drops of blood in under 30 minutes — without requiring trained laboratory personnel. The company's flagship product, TruVerus, combines multiple blood test modalities into a single compact analyzer designed for point-of-care settings such as physician offices, clinics, urgent care centers, and long-term care facilities that lack on-site labs.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.